"Good Morning America" co-host Robin Roberts was recently diagnosed with myelodysplastic syndrome (MDS) and will need an allogenic bone marrow transplant (her sister will be her donor). This blood and bone marrow disease is not a total surprise. Five years ago Roberts underwent both chemotherapy and radiation for breast cancer, which substantially raised her risk of other diseases later in life.
The BEAM chemotherapy I received included the agents carmustine, etoposide, cytarabine, and melphalan (a known potential MDS trigger) but thankfully no radiation. Even so, many chemotherapies are associated with a higher risk of blood diseases. Roberts's situation is a reminder that the side effects of chemotherapy can arise years down the road.
It's a risk I was willing to take and will require a watchful eye for years. Alas, it is one of the issues with a truly myeloablative treatment for MS.
Wikipedia: Some [MDS] patients have a history of exposure to chemotherapy (especially alkylating agents such as melphalan, cyclophosphamide, busulfan, and chlorambucil) or radiation (therapeutic or accidental), or both (e.g., at the time of stem cell transplantation for another disease).
It's a risk I was willing to take and will require a watchful eye for years. Alas, it is one of the issues with a truly myeloablative treatment for MS.
Comment